ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Nonsteroidal antiinflammatory drugs (NSAIDs)"

  • Abstract Number: 2788 • 2017 ACR/ARHP Annual Meeting

    The Risk of Major Toxicity with Aspirin for Primary Cardiovascular Prevention in Rheumatoid Arthritis Patients  Using Nsaids: A Secondary Cohort Analysis of a Randomized Controlled Clinical Trial

    Daniel H. Solomon1, Peter Libby2, Qiuquing Wang3, Katherine E Wolski4, Lisa M Wisniewski4, Neville Yeomans5, Michael Lincoff6, Steven E Nissen7 and M. Elaine Husni8, 1Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2Cardiology, Brigham and Women's Hospital, Boston, MA, 3Cleveland Clinic, Cleveland, OH, 4Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, 5Western Sydney Medical School, Sydney, Australia, 6Cardiology, Cleveland Clinic Foundation, Cleveland, OH, 7Cardiovascular Medicine, Chair, Cleveland Clinic, Cleveland, OH, 8Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH

    Background/Purpose: There are relatively clear guidelines for the use of low dose aspirin in the general population for primary cardiovascular (CV) prevention, but the risk-benefit…
  • Abstract Number: 1L • 2016 ACR/ARHP Annual Meeting

    The Cardiovascular Safety of Celecoxib Versus Ibuprofen or Naproxen in 24,081 Patients with Osteoarthritis or Rheumatoid Arthritis

    M. Elaine Husni1, Daniel H. Solomon2, Katherine E Wolski3, Lisa M Wisniewski3, Steven E Nissen4 and on behalf of the PRECISION Trial Investigators, 1Rheumatology, Cleveland Clinic, Cleveland, OH, 2Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, 4Cardiovascular Medicine, Chair, Cleveland Clinic, Cleveland, OH

    *Both authors (Husni, Solomon) contributed equally and will co present Background/Purpose: The relative cardiovascular (CV) safety of non-selective NSAIDs and selective COX-2 NSAIDs remains unclear. Given…
  • Abstract Number: 2442 • 2016 ACR/ARHP Annual Meeting

    Use of Nonsteroidal Anti-Inflammatory Drugs in Pregnant Women with Inflammatory Arthritis

    Neda Amiri1, Gretchen Bandoli2, Diana L Johnson2 and Christina D. Chambers2, 1Division of Rheumatology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada, 2Pediatrics, University of California, San Diego, La Jolla, CA

    Use of Nonsteroidal Anti-inflammatory Drugs in Pregnant Women with Inflammatory Arthritis Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are generally contraindicated in the third trimester of pregnancy…
  • Abstract Number: 2657 • 2016 ACR/ARHP Annual Meeting

    Withdrawal of Nonsteroidal Anti-Inflammatory Drugs in Rheumatoid Arthritis Patients with Low Disease Activity

    Dong Jin Go1,2, Kichul Shin3, Han Joo Baek4, Seong-Wook Kang5, Young Mo Kang6, Jae-Bum Jun7, Yun Jong Lee8, Sung-Hwan Park9 and Yeong Wook Song10,11, 1Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, The Republic of, 2Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea, The Republic of, 3Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, South Korea, 4Division of Rheumatology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea, 5Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, South Korea, 6Division of Rheumatology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, South Korea, 7Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, The Republic of, 8Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, 9Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, South Korea, 10Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, 11Department of Molecular Medicine and Biopharmaceutical Sciences, BK21 plus Graduate School of Convergence Science and Technology, and College of Medicine or College of Pharmacy, Seoul National University, Seoul, South Korea

    Background/Purpose:  Although nonsteroidal anti-inflammatory drugs (NSAIDs) are effective in relieving joint pain in rheumatoid arthritis (RA) patients, long-term use of NSAIDs can cause adverse effects.…
  • Abstract Number: 1439 • 2015 ACR/ARHP Annual Meeting

    Reducing Gastric Ulcers in Patients with a History of Gastrointestinal (GI) Ulcers Who Require Long-Term High-Dose Non-Steroidal Anti-Inflammatory Drug (NSAID) Therapy

    John Fort1, Robert J. Holt2, Jeffrey D. Kent3 and Alfonso Bello4, 1POZEN Inc., Chapel Hill, NC, 2College of Pharmacy, University of Illinois-Chicago, Vernon Hill, IL, 3Horizon Pharma USA, Inc., Deerfield, IL, 4Illinois Bone & Joint Inst, Glenview, IL

     Background/Purpose: Patients ≥65 taking naproxen with previous GI symptoms have a 29% annual incidence of significant upper gastrointestinal events.(1) Those patients who are older, with…
  • Abstract Number: 249 • 2014 ACR/ARHP Annual Meeting

    A Phase 3 Open-Label Trial of Low-Dose Solumatrix Diclofenac in Patients with Osteoarthritis Pain: Impact of Long-Term Administration on Patient-Reported Outcomes

    Vibeke Strand1, Allan Gibofsky2, Marc Hochberg3, Roy Altman4, Byron Cryer5, Alan Kivitz6, Olaolu Imasogie7 and Clarence Young8, 1Stanford University, Palo Alto, CA, 2Medicine and Public Health, Hospital for Special Surgery, New York, NY, 3University of Maryland School of Medicine, College Park, MD, 4University of California–Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 5University of Texas Southwestern Medical Center, Dallas, TX, 6Altoona Center for Clinical Research, Duncansville, PA, 7Iroko Pharmaceuticals LLC, Philadelphia, PA, 8150 Rouse Boulevard, Iroko Pharmaceuticals, LLC, Phila, PA

    Background/Purpose: Diclofenac is used for the treatment of osteoarthritis (OA), but, like other NSAIDs, it is associated with serious dose-related adverse events. The FDA has…
  • Abstract Number: 243 • 2014 ACR/ARHP Annual Meeting

    Safety of Solumatrix Diclofenac in Adults with Osteoarthritis: Results of a 12-Month, Phase 3 Study

    Roy Altman1, Allan Gibofsky2, Marc C. Hochberg3, Byron Cryer4, Alan J. Kivitz5, Vibeke Strand6, Olaolu Imasogie7 and Clarence Young8, 1University of California–Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 2Medicine and Public Health, Hospital for Special Surgery, New York, NY, 3Division of Rheumatology & Clinical Immunology, University of Maryland School of Medicine, Baltimore, MD, 4University of Texas Southwestern Medical Center, Dallas, TX, 5Altoona Center for Clinical Research, Duncansville, PA, 6Stanford University, Palo Alto, CA, 7Iroko Pharmaceuticals LLC, Philadelphia, PA, 8150 Rouse Boulevard, Iroko Pharmaceuticals, LLC, Phila, PA

    Background/Purpose:   Osteoarthritis (OA) is a frequent cause of disability in adults. NSAIDs such as diclofenac are often prescribed to treat OA pain. However, NSAIDs…
  • Abstract Number: 2235 • 2014 ACR/ARHP Annual Meeting

    Cost-Effectiveness of Long-Term Opioid Use in the Treatment of Knee Osteoarthritis in Older Patients with Multiple Comorbidities  

    Jeffrey N. Katz1, Savannah Smith2, Jamie E. Collins3, Joanne M. Jordan4, David J. Hunter5, Edward H. Yelin6, Lisa Suter7, A. David Paltiel8 and Elena Losina3, 1Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA, 2Orthopedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, 3Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, 4University of North Carolina Dept of Epidemiology, Chapel Hill, NC, 5Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, 6Arthritis Research Group, University of California, San Francisco, San Francisco, CA, 7Medicine, Rheumatol, TAC S541, Yale University, New Haven, CT, 8Yale School of Public Health, New Haven, CT

    Background/Purpose: Because older patients with osteoarthritis (OA) and multiple comorbidities face high risk of toxicity from nonselective non-steroidal antiinflammatory drugs (NSAIDs) and Cox-2 inhibitors, opiates…
  • Abstract Number: 1253 • 2014 ACR/ARHP Annual Meeting

    Anakinra – a Promising New Therapy for Idiopathic Recurrent Pericarditis

    Sonia Jain1, Charat Thongprayoon2, Raul Espinosa1, Sharonne Hayes1, Kyle Klarich1, Kevin Moder3, Nandan Anavekar1, Jae Oh1 and Eric L. Matteson4, 1Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, 2Department of Medicine, Mayo clinic, Rochester, MN, 3Division of Rheumatology, Mayo Clinic, Rochester, MN, 4Rheumatology, Mayo Clinic, Rochester, MN

    Background/Purpose Idiopathic recurrent pericarditis (IRP) is a debilitating condition that can be recalcitrant to conventional therapy. Some patients develop steroid dependency with the attendant risks…
  • Abstract Number: 2681 • 2013 ACR/ARHP Annual Meeting

    Reduced Fertility In Women With Rheumatoid Arthritis: Influence Of Disease Activity and Medication Use

    Jenny Brouwer1,2, Johanna MW Hazes1, Joop SE Laven2 and Radboud JEM Dolhain1, 1Rheumatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, 2Obstetrics & Gynaecology, division of Reproductive Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands

    Background/Purpose: Many female rheumatoid arthritis (RA) patients who try to conceive have a time to pregnancy (TTP) longer than 12 months.  During this period RA…
  • Abstract Number: 2149 • 2013 ACR/ARHP Annual Meeting

    Safety Of Lower-Dose Diclofenac Submicron Particle Capsules Dosed Up To 12 Weeks In Patients With Osteoarthritis

    Clarence Young1 and Marc C. Hochberg2, 1Iroko Pharmaceuticals, Philadelphia, PA, 2Medicine, University of Maryland School of Medicine, Baltimore, MD

    Background/Purpose: Osteoarthritis (OA) is the most common cause of disability in the US and is frequently managed with non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs, including diclofenac,…
  • Abstract Number: 2046 • 2013 ACR/ARHP Annual Meeting

    Lower-Dose Indomethacin Submicron Particle Capsules’ Efficacy In Acute Pain: Results From Two Phase 3 Studies

    Roy D. Altman1, Allan Gibofsky2, Mark Jaros3 and Clarence Young4, 1David Geffen School of Medicine, UCLA, Los Angeles, CA, 2Medicine and Public Health, Hospital for Special Surgery, New York, NY, 3Summit Analytical, Denver, CO, 4Iroko Pharmaceuticals, Philadelphia, PA

    Background/Purpose: Indomethacin is used to treat acute gouty arthritis and other acute pain conditions but, like other NSAIDs, is associated with dose-related gastrointestinal, cardiovascular, and…
  • Abstract Number: 2047 • 2013 ACR/ARHP Annual Meeting

    Lower-Dose Indomethacin Submicron Particle Capsules’ Combined Safety From Two Phase 3 Studies In Patients With Acute Pain Following Elective Surgery

    Allan Gibofsky1, Roy D. Altman2, Clarence Young3, Daniel Solorio4 and Jennifer Nezzer5, 1Medicine and Public Health, Hospital for Special Surgery, New York, NY, 2David Geffen School of Medicine, UCLA, Los Angeles, CA, 3Iroko Pharmaceuticals, Philadelphia, PA, 4Iroko Pharmaceuticals, LLC, Philadelphia, PA, 5Premier Research, Philadelphia, PA

    Background/Purpose: Indomethacin is prescribed to treat acute pain and inflammation but, like other NSAIDs, is associated with dose-dependent gastrointestinal, cardiovascular, and renal adverse events (AEs).…
  • Abstract Number: 1095 • 2013 ACR/ARHP Annual Meeting

    Pooled Safety Data From Randomized, Controlled Trials Of Diclofenac Sodium Topical Gel 1% In Subjects With Acute Pain

    Roy D. Altman1, Helmut Pabst2, Hans-Georg Predel3, Bruno Giannetti4, Ian Burnett5, Morris Gold6 and Evan F. Ekman7, 1David Geffen School of Medicine, UCLA, Los Angeles, CA, 2Independent Physician, Gilching, Germany, 3German Sports University, Cologne, Germany, 4CRM clinical trials GmbH, Rheinbach, Germany, 5Novartis Consumer Health, Nyon, Switzerland, 6Novartis Consumer Health, Parsippany, NJ, 7Southern Orthopaedic Sports Medicine, Columbia, SC

    Background/Purpose: Diclofenac sodium topical gel (DSG) 1% is clinically proven to be effective and well-tolerated for treatment of osteoarthritis pain and could be appropriate to…
  • Abstract Number: 415 • 2012 ACR/ARHP Annual Meeting

    Hypoxia-Induced Endogenous Prostaglandin E2 Negatively Regulates Hypoxia-Enhanced Aberrant Overgrowth of Rheumatoid Synovial Tissue

    Hirofumi Mitomi1, Hidehiro Yamada1, Toshiko Nozaki Shibata1, Hiroshi Ito1, Yoshioki Yamasaki2, So Nomoto3, Atsushi Kusaba4, Hiroki Yamashita4 and Shoichi Ozaki1, 1Internal Medicine, St. Marianna University, Kawasaki, Japan, 2Medicine, St. Marianna University, Kawasaki, Japan, 3Department of Orthopedic Surgery and Rheumatology, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Japan, 4Institute of Rheumatology, Ebina General Hospital, Ebina, Japan

    Background/Purpose: During isometric exercise, the synovial joint tissue is prone to hypoxia, which is further enhanced in the presence of synovial inflammation. Hypoxia is also…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology